#USA #Houston #Iterion Therapeutics #Tegavivint #Wnt Pathway

Introduction

Iterion Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering treatments for cancers driven by the Wnt/b-catenin signaling pathway, recently presented initial compelling data regarding their novel therapy, Tegavivint. The findings, shared at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, represent a significant step forward in addressing an area of critical unmet medical need: advanced hepatocellular carcinoma (HCC) driven by Wnt pathway mutations.

Overview of Tegavivint

Tegavivint is recognized as a first-in-class treatment designed specifically to target the oncogenic effects of Wnt/b-catenin pathway mutations. The Phase 1/2 trial presented showcased its capacity to inhibit these pathways by disrupting the TBL1β-catenin transcriptional complex, proving to be effective in patients with Wnt-pathway activating mutations (WPAMs). In clinical terms, Tegavivint has shown substantial tolerance amongst patients while exhibiting promising monotherapy clinical responses.

Study Findings

The clinical trial included 40 patients who had previously undergone a median of two lines of systemic therapy. Remarkably, a significant 73% of these participants had tumors with WPAMs, identifiable through ctDNA testing.

• - Efficacy Results: Among those treated with Tegavivint, a 22% overall response rate (ORR) was observed in patients with WPAM+ tumors, alongside an impressive 89% disease control rate (DCR) and a median progression-free survival (mPFS) of 8 months. Notably, tumor shrinkage was recorded in 40% of evaluable patients treated at recommended doses, reinforcing the targeted approach of this therapy.

• - Safety Profile: Tegavivint was well tolerated overall; the treatment-related adverse events (TRAEs) were predominantly mild (Grade 1 or 2), with the most common issues being fatigue, hyperbilirubinemia, and anemia. One significant finding was that Grade 3 anemia was observed at the highest dose, which was reversible. This led to a recommended dosage ranging from 3 to 6.5 mg/kg, indicating a careful balance between efficacy and safety.

Implications for Advanced HCC Patients

According to Dr. David Hsieh, who presented the data, the findings highlight a population within advanced HCC patients whose tumors are driven by specific mutations in the Wnt pathway. Until now, this group has lacked targeted treatment options. Dr. Hsieh emphasized that the encouraging clinical activity noted with Tegavivint marks a potential turning point in the search for novel therapies for these biomarker-selected patients.

Future Directions

Following the Phase 1/2 study results, Iterion Therapeutics is poised to continue its focused approach in advancing Tegavivint for advanced HCC as well as in other Wnt-driven cancers, such as metastatic colorectal cancer (mCRC) and pediatric osteosarcoma. The company has successfully garnered $26 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT), bolstering its commitment to further research and development.

Conclusion

Tegavivint represents a groundbreaking advancement in the treatment of Wnt-driven tumors, particularly in advanced hepatocellular carcinoma. The data presented at ASCO signify not just hope for patients with limited options but also ignite new possibilities for targeted therapies in oncology. Iterion Therapeutics continues to pave the way in cancer research with their innovative approach, shedding light on previously underserved cancers driven by genetic mutations.